LOGIN  |  REGISTER
Cue Biopharma

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

August 27, 2025 | Last Trade: US$33.26 0.00 0.00

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in September:

  • 2025 Wells Fargo Healthcare Conference – Fireside chat on Wednesday, September 3, 2025 at 12:45 p.m. ET
  • Cantor Global Healthcare Conference 2025 – Fireside chat on Thursday, September 4, 2025 at 1:00 p.m. ET
  • H.C. Wainwright 27th Annual Global Investment Conference – Fireside chat on Tuesday, September 9, 2025 at 9:00 a.m. ET
  • Stifel 2025 Virtual Immunology & Inflammation Forum – Presentation on Monday, September 15, 2025 at 9:30 a.m. ET

To access the live webcasts or subsequent archived recordings of the fireside chats and presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.

RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.

RAPT Investor Contact:
Sylvia Wheeler
This email address is being protected from spambots. You need JavaScript enabled to view it. 

RAPT Media Contact:
Aljanae Reynolds
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page